Clinical trials: Normal Lungs
Breast Cancer, Pancreatic Cancer
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
This study is a Phase I, first in human, dose-escalation study of MORAb-066, an investigational humanized immunoglobulin G (IgG) monoclonal antibody (mAb) that targets TF-expressing malignancies that include breast, pancreatic…
- Conditions
- Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01761240
- Testing
- MORAb-066
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Morphotek
Neoplasms
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent…
- Trial name
- Meteor 1 (NCT02783300)
- Testing
- GSK3326595, Pembrolizumab
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 297 people
- Sponsor
- GlaxoSmithKline
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Solid Tumor
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal…
- Trial name
- MasterKey-01 (NCT04209465)
- Testing
- BDTX-189
- Where
- 38 sites in United States, Denmark and 2 more
- Volunteers
- 91 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Breast Carcinoma, Colorectal Carcinoma
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
This clinical trial studies the effectiveness of a web-based cancer education tool called Helping Oncology Patients Explore Genomics (HOPE-Genomics) in improving patient knowledge of personal genomic testing results and cancer…
- Conditions
- Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT04905082
- Testing
- Best Practice, Educational Intervention, Genomic Profile
- Where
- United States
- Volunteers
- 465 people
- Sponsor
- City of Hope Medical Center
Chronic Spontaneous Urticaria
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
A safety extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria (CSU) patients who completed study CQGE031C2201
- Trial name
- NCT02649218
- Testing
- Ligelizumab
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer
Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Research studies have shown a strong association between cancer and blood clots in the veins (also known as deep vein thrombosis).
- Trial name
- MicroTEC (NCT00908960)
- Testing
- Enoxaparin
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Beth Israel Deaconess Medical Center
Systemic Sclerosis, Shortness of Breath
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
The purpose of this study is to determine the clinical characteristics and hemodynamic profiles that predict exercise induced pulmonary hypertension in 15 patients with systemic sclerosis.
- Conditions
- Systemic Sclerosis, Shortness of Breath, Pulmonary Hypertension
- Trial name
- NCT01051960
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, Los Angeles
Neoplasms
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
Background: Some people have cancers that don't respond to standard treatments. In these cases, doctors may try to use drugs to slow the growth of the cancer.
- Trial name
- NCT02192541
- Testing
- Ziv-Aflibercept, Ganetespib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Systemic Sclerosis, Scleroderma
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
The purpose of this research study is to learn about the effects of the medication ixazomib in participants with scleroderma/systemic sclerosis including its safety and tolerability, its effects on skin, lungs and other organs…
- Conditions
- Systemic Sclerosis, Scleroderma, Diffuse Systemic Sclerosis, Diffuse Scleroderma
- Trial name
- NCT04837131
- Testing
- Ixazomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Michael M. Pham
Locally Advanced or Metastatic Solid Tumors
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2…
- Trial name
- NCT03150810
- Testing
- Pamiparib, Temozolomide
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 139 people
- Sponsor
- BeiGene
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa [MK-3475A] administered subcutaneously (SC) over pembrolizumab [MK-3475]…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06099782
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 147 people
- Sponsor
- Merck Sharp & Dohme LLC
Interstitial Lung Disease, Connective Tissue Disease
A Clinical Trial for CTD-ILD Treatment
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
- Trial name
- NCT01424033
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Solitary Pulmonary Nodule, Biopsy, Fine-Needle
iNod System Human Feasibility Assessment
The purpose of this study is to demonstrate feasibility to access, visualize, and obtain specimens adequate for cytology of lung lesions in subjects with suspected lung cancer when using the iNod System.
- Trial name
- iNod (NCT02832284)
- Testing
- iNod System
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Boston Scientific Corporation
Lung Diseases, Pulmonary Fibrosis
Scleroderma Lung Disease
To evaluate the efficacy and safety of cyclophosphamide versus placebo for the prevention and progression of symptomatic pulmonary disease in patients with systemic sclerosis.
- Conditions
- Lung Diseases, Pulmonary Fibrosis, Systemic Scleroderma, Scleroderma, Systemic
- Trial name
- SLS (NCT00004563)
- Testing
- Cyclophosphamide
- Volunteers
- 158 people
- Sponsor
- The University of Texas Health Science Center, Houston
Colorectal Neoplasms, Lung Neoplasms
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.
- Conditions
- Colorectal Neoplasms, Lung Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT00976508
- Testing
- figitumumab, pegvisomant
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 24 people
- Sponsor
- Pfizer
Dermatitis, Atopic
Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)
The Early Prevention of Asthma in Atopic Children (EPAAC™). 24 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24 months old children.
- Trial name
- NCT00152464
- Testing
- Levocetirizine
- Volunteers
- 514 people
- Sponsor
- UCB Pharma SA
Melanoma, Prostate Cancer
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with…
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- IVY (NCT02009449)
- Testing
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- Where
- 10 sites in United States
- Volunteers
- 353 people
- Sponsor
- Eli Lilly and Company
Lung Cancer, Breast Cancer
Iressa Follow-up Trial
The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).
- Trial name
- NCT00357734
- Testing
- Gefitinib
- Where
- 7 sites in Germany
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Systemic Sclerosis-associated Interstitial Lung Disease
Abituzumab in SSc-ILD
The purpose of this trial was to compare two doses of abituzumab with placebo and determine whether abituzumab was more effective, safer, would be better tolerated and could provoke better immune response than placebo in the…
- Trial name
- NCT02745145
- Testing
- Abituzumab 1500 mg, Abituzumab 500 mg
- Where
- 55 sites in United States, Argentina and 7 more
- Volunteers
- 24 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.